<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="551d4eda-5c34-4a2a-89f8-661372342fe5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use FRUZAQLA safely and effectively. See full prescribing information for FRUZAQLA.<br/>
      <br/> FRUZAQLA<sup>Â®</sup> (fruquintinib) capsules, for oral use<br/> Initial U.S. Approval: 2023</title>
   <effectiveTime value="20250306"/>
   <setId root="186d786e-dc8a-45f2-b5e1-01ac0201879f"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="039997266" root="1.3.6.1.4.1.519.1"/>
            <name>Takeda Pharmaceuticals America, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="56cbf735-2ed3-49ab-ac1d-c5c6c24d5c98"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250206"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63020-210" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Fruzaqla</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>fruquintinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="49DXG3M5ZW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FRUQUINTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="49DXG3M5ZW" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FRUQUINTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="I753WB2F1M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 5</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="21"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63020-210-21" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217564" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" displayName="YELLOW" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>yellow opaque cap and white opaque body</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">HM013;1mg</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63020-225" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Fruzaqla</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>fruquintinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="49DXG3M5ZW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FRUQUINTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="49DXG3M5ZW" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FRUQUINTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="21"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63020-225-21" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217564" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48326" displayName="RED" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>red opaque cap and white opaque body</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">HM013;5mg</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="58dc5456-9314-472f-8827-db427ec69791"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col width="90%" align="left" valign="top"/>
                           <col width="10%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.2">2.2</linkHtml>)</td>
                                 <td>2/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="191cc303-9814-4bf1-aa20-5899ef007567"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1.	INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidineâ, oxaliplatinâ, and irinotecanâbased chemotherapy, an antiâVEGF therapy, and, if RAS wildâtype and medically appropriate, an anti-EGFR therapy.</paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidineâ, oxaliplatinâ, and irinotecanâbased chemotherapy, an antiâVEGF therapy, and, if RAS wildâtype and medically appropriate, an anti-EGFR therapy. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="4718d7ab-b88e-4d81-900a-7d3b00e24a5a"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2.	DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The recommended dose of FRUZAQLA is 5 mg orally once daily, with or without food for the first 21 days of each 28-day cycle. (<linkHtml href="#S2.1">2.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="c009f09e-15d0-41e2-aa7b-a4f2244b01c9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1.	Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dose of FRUZAQLA is 5 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take FRUZAQLA with or without food <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content> at approximately the same time each day.</paragraph>
                        <paragraph>Swallow the FRUZAQLA capsule whole.</paragraph>
                        <paragraph>Take a missed dose if less than 12 hours have passed since the missed scheduled dose. Do not take two doses on the same day to make up for a missed dose.</paragraph>
                        <paragraph>Do not take an additional dose if vomiting occurs after taking FRUZAQLA but continue with the next scheduled dose.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="4b008c53-fe70-489d-8e56-f2dd9f60520e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2.	Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>The recommended dose reductions for adverse reactions are provided in Table 1.</paragraph>
                        <table ID="table1" width="80%">
                           <caption>Table 1:	Recommended Dose Reductions for FRUZAQLA</caption>
                           <col width="50%"/>
                           <col width="50%"/>
                           <thead>
                              <tr>
                                 <th align="left" valign="middle" styleCode="Lrule Rrule">Dose Level</th>
                                 <th align="left" valign="middle" styleCode="Lrule Rrule">FRUZAQLA Dosage</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Botrule">First dose reduction</td>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Botrule">4 mg orally once daily</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">Second dose reduction</td>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">3 mg orally once daily</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Permanently discontinue FRUZAQLA in patients unable to tolerate 3 mg orally once daily.</paragraph>
                        <paragraph>The recommended dosage modifications for adverse reactions are provided in Table 2.</paragraph>
                        <table ID="table2" width="80%">
                           <caption>Table 2:	Recommended Dosage Modifications for FRUZAQLA</caption>
                           <col width="33%" align="left" valign="top"/>
                           <col width="33%" align="left" valign="top"/>
                           <col width="34%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" valign="middle">Adverse Reaction</th>
                                 <th styleCode="Rrule" valign="middle">Severity<footnote ID="t2f1">Severity as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</footnote>
                                 </th>
                                 <th styleCode="Rrule" valign="middle">FRUZAQLA Dosage Modification</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Hypertension 
                                    <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Grade 3</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Withhold FRUZAQLA for Grade 3 hypertension that persists despite optimal anti-hypertensive therapy.</item>
                                       <item>If hypertension fully resolves or recovers to Grade 1, resume at the next lower dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule">Grade 4</td>
                                 <td styleCode="Rrule">Permanently discontinue FRUZAQLA.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Hemorrhagic Events
                              <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Grade 2</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Withhold FRUZAQLA until bleeding fully resolves or recovers to Grade 1.</item>
                                       <item>Resume at the next lower dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule">Grade 3 or Grade 4</td>
                                 <td styleCode="Rrule">Permanently discontinue FRUZAQLA.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="3">Hepatotoxicity
                              <content styleCode="italics">[see  <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times upper limit of normal (ULN), or greater than 3 times baseline if baseline was abnormal; <br/>
                                    <content styleCode="underline">or</content>
                                    <br/> bilirubin greater than 1.5 times ULN, or greater than 1.5 times baseline if baseline was abnormal</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Withhold FRUZAQLA and monitor AST, ALT and total bilirubin until resolution to Grade 1 or baseline.</item>
                                       <item>Resume at the next lower dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule">ALT or AST greater than 3 times ULN with concurrent total bilirubin greater than 2 times ULN (in the absence of cholestasis or hemolysis)</td>
                                 <td styleCode="Rrule">Permanently discontinue FRUZAQLA.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">AST or ALT greater than 20 times ULN if baseline was normal, or greater than 20 times baseline if baseline was abnormal; <br/>
                                    <content styleCode="underline">or</content>
                                    <br/> bilirubin greater than 10 times ULN if baseline was normal, or greater than 10 times baseline if baseline was abnormal</td>
                                 <td styleCode="Rrule">Permanently discontinue FRUZAQLA.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Proteinuria
                              <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">2 grams or greater proteinuria in 24 hours</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Withhold FRUZAQLA until proteinuria fully resolves or is &lt;1 gram/24 hours.</item>
                                       <item>Upon recovery, resume at the next lower dose level.</item>
                                    </list>Permanently discontinue FRUZAQLA for nephrotic syndrome or if proteinuria does not recover to &lt;1 gram/24 hours.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Palmar-plantar erythrodysesthesia (PPE)
                              <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Grade 2</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Withhold FRUZAQLA and initiate supportive treatment.</item>
                                       <item>If toxicity fully resolves or recovers to Grade 1, resume at the same dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Grade 3</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Withhold FRUZAQLA and initiate supportive treatment.</item>
                                       <item>If toxicity fully resolves or recovers to Grade 1, resume at the next lower dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Other Adverse Reactions
                              <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Grade 3</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Withhold FRUZAQLA.</item>
                                       <item>If toxicity fully resolves or recovers to Grade 1, resume at the next lower dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Grade 4</td>
                                 <td styleCode="Rrule">Discontinue FRUZAQLA.<br/>Consider resuming FRUZAQLA at the next lower dose level only if the toxicity is non-life threatening and fully resolves or recovers to Grade 1 and the potential benefit outweighs the risks.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="e05802d7-2644-4090-8ae5-d0f97d7ffecd"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3.	DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Capsules:</paragraph>
                  <list listType="unordered">
                     <item>1 mg: size 3 hard gelatin capsule with standard yellow opaque cap and white opaque body, imprinted with âHM013â over â1 mgâ on the body in black ink.</item>
                     <item>5 mg: size 1 hard gelatin capsule with a red opaque cap and white opaque body, imprinted with âHM013â over â5 mgâ on the body in black ink.</item>
                  </list>
               </text>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Capsules: 1 mg and 5 mg. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="2d20d62b-3318-4d8c-baa4-c847c95513d8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4.	CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="ec21602f-faef-45ef-8323-c2f133e1c011"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5.	WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Hypertension:</content> Control blood pressure prior to treatment and monitor during treatment. Manage with anti-hypertensive medications and adjustment of the dose of FRUZAQLA, if necessary. Withhold, dose reduce, or permanently discontinue based on severity of hypertension. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hemorrhagic Events:</content> Closely monitor patients who are at risk for bleeding. Withhold, reduce dose, or permanently discontinue FRUZAQLA based on severity and persistence of hemorrhage. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Infections:</content> Monitor for infection during treatment and withhold FRUZAQLA during active infections. Do not start FRUZAQLA in patients with active infections. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Gastrointestinal (GI) Perforation:</content> Periodically monitor for GI perforation. Permanently discontinue FRUZAQLA in patients who develop GI perforation or fistula. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity:</content> Monitor liver laboratory tests prior to the start of FRUZAQLA and periodically during treatment. Withhold, reduce the dose, or permanently discontinue based on severity. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Proteinuria: </content>Monitor urine protein. Discontinue FRUZAQLA for nephrotic syndrome (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Palmar-Plantar Erythrodysesthesia:</content> Withhold FRUZAQLA based on severity. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.7">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Posterior Reversible Encephalopathy Syndrome (PRES):</content> Immediately discontinue FRUZAQLA if PRES is suspected and confirmed via Magnetic Resonance Imaging (MRI). (<linkHtml href="#S5.8">5.8</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Impaired Wound Healing:</content> Withhold FRUZAQLA for 2 weeks before major surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of FRUZAQLA after resolution of wound healing complications has not been established. (<linkHtml href="#S5.9">5.9</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Arterial Thromboembolic Events:</content> Initiation of FRUZAQLA in patients with a recent history of thromboembolic events should be carefully considered. Discontinue FRUZAQLA in patients who develop arterial thromboembolism. (<linkHtml href="#S5.10">5.10</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Allergic Reactions to FD&amp;C Yellow No. 5 (Tartrazine) and No. 6 (Sunset Yellow FCF): </content>Contains FD&amp;C Yellow No. 5 (tartrazine) and No. 6 (sunset yellow FCF) as color additives, which may cause allergic reactions (including bronchial asthma) in certain susceptible patients. (<linkHtml href="#S5.11">5.11</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity:</content> Can cause fetal harm. Advise patients of reproductive potential of the potential risk to the fetus and to use effective contraception. (<linkHtml href="#S5.12">5.12</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="e942722f-14ae-45e5-81e7-74388c374dd9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1.	Hypertension</title>
                     <text>
                        <paragraph>FRUZAQLA can cause hypertension. Hypertension occurred in 450 of 911 (49%) patients with mCRC treated with FRUZAQLA, including Grade 3-4 events in 19%, and hypertensive crisis in three patients (0.3%). The median time to first onset of hypertension was 14 days from first dose of FRUZAQLA.</paragraph>
                        <paragraph>Do not initiate FRUZAQLA unless blood pressure is adequately controlled. Monitor blood pressure weekly the first month, at least monthly thereafter and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue FRUZAQLA based on the severity of hypertension <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="2156e7af-a435-41ed-a900-ea3b318905ce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2.	Hemorrhagic Events</title>
                     <text>
                        <paragraph>FRUZAQLA can cause serious hemorrhagic events, which may be fatal. In 911 patients with mCRC treated with FRUZAQLA, 6% of patients experienced a gastrointestinal hemorrhage, including 13 patients (1%) with a Grade â¥3 event and 2 patients with fatal hemorrhages.</paragraph>
                        <paragraph>Permanently discontinue FRUZAQLA in patients with severe or life-threatening hemorrhage. Monitor the International Normalized Ratio (INR) levels in patients receiving anticoagulants <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="fb094e94-9c0f-48a5-8eac-3f39e28d9722"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3.	Infections</title>
                     <text>
                        <paragraph>FRUZAQLA can cause an increased risk of infections, including fatal infections. In 781 patients treated with FRUZAQLA across three randomized, placebo-controlled trials, the overall incidence of infections was higher (18% vs. 12%) including for fatal infections (1% vs. 0.3%) as compared to the placebo arms (n=391).</paragraph>
                        <paragraph>In 911 patients with mCRC treated with FRUZAQLA, the most common infections were urinary tract infections (6.8%), upper respiratory tract infections (3.2%) and pneumonia (2.5%); fatal infections included pneumonia (0.4%), sepsis (0.2%), bacterial infection (0.1%), lower respiratory tract infection (0.1%), and septic shock (0.1%).</paragraph>
                        <paragraph>Withhold FRUZAQLA for Grade 3 or 4 infections, or worsening infection of any grade. Resume FRUZAQLA at the same dose when the infection has resolved.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="b8ba25c4-31d4-4cc4-bd68-7ebeb03320ab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4.	Gastrointestinal Perforation</title>
                     <text>
                        <paragraph>FRUZAQLA can cause gastrointestinal perforation. In 911 patients with mCRC treated with FRUZAQLA, 12 patients (1.3%) experienced a Grade â¥3 gastrointestinal perforation, including one fatal event.</paragraph>
                        <paragraph>Permanently discontinue FRUZAQLA in patients who develop gastrointestinal perforation or fistula.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="b3eb0809-b4e5-438b-b7f4-6c84921a76a3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5.	Hepatotoxicity</title>
                     <text>
                        <paragraph>FRUZAQLA can cause liver injury. In 911 patients with mCRC treated with FRUZAQLA, 48% experienced increased ALT or AST, including Grade â¥3 events in 5%, and fatal events in 0.2%. Median time to first onset of elevated liver enzymes was 29 days from first dose of FRUZAQLA.</paragraph>
                        <paragraph>Monitor liver function tests (ALT, AST, and bilirubin) before initiation and periodically throughout treatment with FRUZAQLA. Temporarily hold and then reduce or permanently discontinue FRUZAQLA depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="6d5b053f-2f1c-49e0-974b-4f8d50218935"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6.	Proteinuria</title>
                     <text>
                        <paragraph>FRUZAQLA can cause proteinuria. In 911 patients with mCRC treated with FRUZAQLA, 36% experienced proteinuria and 2.5% of patients experienced Grade â¥3 events. Median time to first onset of proteinuria was 22 days from first dose of FRUZAQLA.</paragraph>
                        <paragraph>Monitor for proteinuria before initiation and periodically throughout treatment with FRUZAQLA. For proteinuria â¥2 g/24 hours, withhold FRUZAQLA until improvement to â¤Grade 1 proteinuria, resume FRUZAQLA at a reduced dose. Discontinue FRUZAQLA in patients who develop nephrotic syndrome <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="fae5d09e-61c2-4e4b-84ae-c57095965ee1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7.	Palmar-Plantar Erythrodysesthesia (PPE)</title>
                     <text>
                        <paragraph>FRUZAQLA can cause PPE. In 911 patients with mCRC treated with FRUZAQLA, PPE occurred in 35%, including 8% with Grade 3 events. Median time to first onset of PPE was 19 days from first dose of FRUZAQLA.</paragraph>
                        <paragraph>Based on severity, withhold FRUZAQLA and then resume at the same or reduced dose <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="1e459791-a7ae-4786-b0ad-fd53ac42d9d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8.	Posterior Reversible Encephalopathy Syndrome (PRES)</title>
                     <text>
                        <paragraph>FRUZAQLA can cause PRES, a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI. PRES occurred in one of 911 patients with mCRC treated with FRUZAQLA.</paragraph>
                        <paragraph>Perform an evaluation for PRES in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function. Discontinue FRUZAQLA in patients who develop PRES.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="d774b39f-225d-49b9-8f80-715461024a76"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9.	Impaired Wound Healing</title>
                     <text>
                        <paragraph>Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. In 911 patients with mCRC treated with FRUZAQLA, 1 patient experienced a Grade 2 event of wound dehiscence.</paragraph>
                        <paragraph>Do not administer FRUZAQLA for at least 2 weeks prior to major surgery.</paragraph>
                        <paragraph>Do not administer FRUZAQLA for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of FRUZAQLA after resolution of wound healing complications has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="b4b4656d-1acc-43e4-ab1b-b062c65f7f17"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10.	Arterial Thromboembolic Events</title>
                     <text>
                        <paragraph>FRUZAQLA may increase the risk of arterial thromboembolic events. In 911 patients with mCRC treated with FRUZAQLA, 7 patients (0.8%) experienced an arterial thromboembolic event; additionally, FRUZAQLA studies excluded patients with clinically significant cardiovascular disease, uncontrolled hypertension, or with thromboembolic events within the prior 6 months. Initiation of FRUZAQLA in patients with a recent history of thromboembolic events should be carefully considered. In patients who develop arterial thromboembolism discontinue FRUZAQLA.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="769edbc7-3441-4d3f-a2fb-84a6cb14adfb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11.	Allergic Reactions to FD&amp;C Yellow No. 5 (Tartrazine) and No. 6 (Sunset Yellow FCF)</title>
                     <text>
                        <paragraph>FRUZAQLA 1 mg capsules contain FD&amp;C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.</paragraph>
                        <paragraph>FRUZAQLA 1 mg contains FD&amp;C Yellow No. 6 (sunset yellow FCF), which may cause allergic reactions.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="d24ff85e-e134-41fd-8ad5-2d0d0cd8bc1c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12.	Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings in animal studies and its mechanism of action, FRUZAQLA can cause fetal harm when administered to pregnant women. In an embryo-fetal developmental study in rats, embryotoxic and teratogenic effects were observed at exposures below the clinical exposure <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Advise pregnant women of the potential risk to a fetus. Advise females of childbearing potential and males with female partners of childbearing potential to use effective contraception during treatment with FRUZAQLA and for 2 weeks after the last dose <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="2fe9525d-a3c4-4ca7-bfb5-cde536226d98"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6.	ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Hypertension <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                     <item>Hemorrhagic Events <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                     <item>Infections <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</item>
                     <item>Gastrointestinal Perforation <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</item>
                     <item>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>].</content>
                     </item>
                     <item>Proteinuria <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</item>
                     <item>Palmar-Plantar Erythrodysesthesia (PPE) <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</item>
                     <item>Posterior Reversible Encephalopathy Syndrome (PRES) <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence â¥20%) are hypertension, palmar-plantar erythrodysesthesia, proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America, Inc. at 1-844-662-8532 or FDA at 1-800-FDA-1088 or <linkHtml href="www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="ace090a7-5959-466c-955d-ec4ee3c95065"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1.	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The pooled safety population described in the WARNINGS AND PRECAUTIONS and below reflects exposure to FRUZAQLA as a single agent in 911 patients with mCRC who were enrolled in three randomized, placebo-controlled studies (FRESCO-2, FRESCO and 2012-013-00CH1) (N=781); three open-label studies (2009-013-00CH1, 2012-013-00CH3 and 2015-013-00US1) (N=124); and an open-label lead-in cohort of FRESCO-2 (N=6). Among the 911 patients who received FRUZAQLA, 23% were exposed for 6 months or longer and 3.5% were exposed for greater than one year. These patients received at least one dose of FRUZAQLA at the recommended dosage of 5 mg daily for the first 21 days of each 28-day cycle. The median age was 60 years (range: 23 to 82) and 34% were 65 years of age or older. The most common adverse reactions (incidence â¥20%) that occurred in pooled monotherapy studies were hypertension, PPE, proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metastatic Colorectal Cancer</content>
                           <br/>
                           <content styleCode="italics">FRESCO-2 Study</content>
                           <br/>The safety of FRUZAQLA was evaluated in FRESCO-2, a randomized, double-blind, placebo-controlled study <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. Patients received either FRUZAQLA 5 mg daily for the first 21 days of each 28-day cycle plus best supportive care (BSC) (n=456) or matching placebo plus BSC (n=230).</paragraph>
                        <paragraph>The median duration of therapy with FRUZAQLA was 3 months (range: 0.3 to 19.1 months).</paragraph>
                        <paragraph>Serious adverse reactions occurred in 38% of patients treated with FRUZAQLA. Serious adverse reactions in â¥2% of patients treated with FRUZAQLA included hemorrhage (2.2%) and gastrointestinal perforation (2.0%). Fatal adverse reaction(s) occurred in 14 (3.1%) patients who received FRUZAQLA. Fatal adverse reactions occurring in â¥2 patients include pneumonia (n=3), sepsis/septic shock (n=2), and hepatic failure/encephalopathy (n=2).</paragraph>
                        <paragraph>Adverse reactions leading to treatment discontinuation occurred in 20% of patients treated with FRUZAQLA. Adverse reactions leading to treatment discontinuations of FRUZAQLA in â¥1% of patients were asthenia and gastrointestinal perforation.</paragraph>
                        <paragraph>Dose interruptions of FRUZAQLA due to an adverse reaction occurred in 47% of patients. Adverse reactions leading to dose interruptions of FRUZAQLA in â¥2% of patients were PPE, proteinuria, asthenia, abdominal pain, hypertension, vomiting, and diarrhea.</paragraph>
                        <paragraph>Dose reductions of FRUZAQLA due to an adverse reaction occurred in 24% of patients. Adverse reactions leading to dose reductions of FRUZAQLA in â¥2% of patients were PPE, hypertension and asthenia.</paragraph>
                        <paragraph>Table 3 summarizes the adverse reactions in FRESCO-2.</paragraph>
                        <table ID="table3" width="80%">
                           <caption>Table 3:	Adverse Reactions (â¥10%) in Patients who Received FRUZAQLA and with a Difference Between Arms of â¥5% Compared to Placebo in FRESCO-2 (All Grades)</caption>
                           <col width="46%"/>
                           <col width="13%"/>
                           <col width="14%"/>
                           <col width="13%"/>
                           <col width="14%"/>
                           <thead>
                              <tr>
                                 <th align="left" valign="middle" styleCode="Lrule Rrule">Adverse Reaction</th>
                                 <th align="center" valign="middle" styleCode="Rrule" colspan="2">FRUZAQLA (N=456)</th>
                                 <th align="center" valign="middle" styleCode="Rrule" colspan="2">Placebo (N=230)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule"/>
                                 <td align="center" valign="middle" styleCode="Rrule">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule">
                                    <content styleCode="bold">Grade 3 or 4 (%)</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule">
                                    <content styleCode="bold">Grade 3 or 4 (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">General</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Fatigue<footnote ID="t3f1">Represents a composite of multiple related terms.</footnote>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">53</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">12</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">39</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">4.8</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Vascular</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Hypertension<footnoteRef IDREF="t3f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">38</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">14</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">9</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.9</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Gastrointestinal</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Stomatitis<footnoteRef IDREF="t3f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">31</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.2</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">7.8</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.4</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Abdominal Pain<footnoteRef IDREF="t3f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">25</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">3.5</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">20</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">3</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Diarrhea<footnoteRef IDREF="t3f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">24</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">3.7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">11</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Endocrine Disorders</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Hypothyroidism</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">21</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.4</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.4</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Skin and Subcutaneous</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Palmar-plantar erythrodysesthesia (hand-foot skin reactions)</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">19</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Renal</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Proteinuria<footnoteRef IDREF="t3f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">18</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.8</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">5</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.9</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Respiratory</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Dysphonia<footnoteRef IDREF="t3f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">18</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">5</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Musculoskeletal</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Musculoskeletal Pain<footnoteRef IDREF="t3f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">16</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.1</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Arthralgia</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">11</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.9</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">4.3</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other important adverse reactions (all grades) that occurred in &lt;10% of patients treated with FRUZAQLA included urinary tract infection (4.6%), epistaxis (3.9%), proctalgia (3.5%), pneumonia (2.4%), gastrointestinal hemorrhage (1.5%), gastrointestinal perforation (1.3%), pancreatitis (0.7%), thrombotic microangiopathy (0.2%), and posterior reversible encephalopathy syndrome (0.2%).</paragraph>
                        <paragraph>Table 4 provides laboratory abnormalities observed in FRESCO-2.</paragraph>
                        <table ID="table4" width="80%">
                           <caption>Table 4:	Select Laboratory Abnormalities Worsening from Baseline Occurring in â¥20% of Patients in FRESCO-2</caption>
                           <col width="35%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <thead>
                              <tr>
                                 <th align="left" valign="middle" styleCode="Lrule Rrule Botrule" rowspan="2">Laboratory<footnote ID="t4f1">Graded according to NCI CTCAE version 5.0.</footnote>
                                    <br/>Abnormality</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule" colspan="2">FRUZAQLA (N=456)<footnote ID="t4f2">Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: FRUZAQLA (range: 409-444) and placebo (range: 195-216).</footnote>
                                 </th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule" colspan="2">Placebo (N=230)<footnoteRef IDREF="t4f2"/>
                                 </th>
                              </tr>
                              <tr>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">All Grade<br/>(%)</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">Grade 3 or 4<br/>(%)</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">All Grades<br/>(%)</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">Grade 3 or 4<br/>(%)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Chemistry</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Triglycerides Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">53</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.8</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">22</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Cholesterol Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">37</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.9</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">22</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.9</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Aspartate Aminotransferase Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">36</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">4.3</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">24</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.9</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Albumin Decreased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">35</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">32</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.4</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Sodium Decreased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">35</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.1</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">27</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.9</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Alanine Aminotransferase Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">34</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">5</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">22</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.4</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Bilirubin Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">30</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">21</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">8</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Alkaline Phosphatase Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">20</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">27</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.5</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Magnesium Decreased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">20</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.5</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">10</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.5</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Hematology</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Lymphocytes Decreased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">30</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">32</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">4.7</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Platelets Decreased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">30</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.2</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">4.7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Activated Partial Thromboplastin Time Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">21</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">18</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other clinically relevant laboratory abnormalities (all grades) that occurred in &lt;20% of patients treated with FRUZAQLA included pancreatic enzymes increased (3.9%).</paragraph>
                        <paragraph>
                           <content styleCode="italics">FRESCO Study</content>
                           <br/>The safety of FRUZAQLA was evaluated in FRESCO, a randomized, double-blind, placebo-controlled study <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. Patients received either FRUZAQLA 5 mg daily for the first 21 days of each 28-day cycle plus BSC (n=278) or matching placebo plus BSC (n=137).</paragraph>
                        <paragraph>The median duration of therapy with FRUZAQLA was 3.68 months (range: 0.3 to 22.1 months).</paragraph>
                        <paragraph>Serious adverse reactions occurred in 15% of patients treated with FRUZAQLA. Serious adverse reactions in â¥2% of patients included intestinal obstruction (2.9%) and hemorrhage (2.2%). Fatal adverse reaction(s) occurred in 7 (2.5%) patients who received FRUZAQLA including cerebral infarction (n=1), gastrointestinal hemorrhage (n=1), hemoptysis (n=1), bacterial infection (n=1), lung/lower respiratory infection (n=2), and multiple organ dysfunction (n=1).</paragraph>
                        <paragraph>Adverse reactions leading to treatment discontinuation occurred in 15% of patients who received FRUZAQLA. Adverse reactions leading to treatment discontinuations of FRUZAQLA in â¥1% were intestinal obstruction, proteinuria and hepatic function abnormalities.</paragraph>
                        <paragraph>Dose interruptions of FRUZAQLA due to an adverse reaction occurred in 35% of patients. Adverse reactions leading to dose interruptions of FRUZAQLA in â¥2% of patients were PPE, proteinuria, platelet count decreased, ALT increased, hypertension, and diarrhea.</paragraph>
                        <paragraph>Dose reductions of FRUZAQLA due to an adverse reaction occurred in 24% of patients. Adverse reactions leading to dose reduction of FRUZAQLA in â¥2% of patients were PPE, proteinuria, and hypertension.</paragraph>
                        <paragraph>Table 5 summarizes the adverse reactions in FRESCO.</paragraph>
                        <table ID="table5" width="80%">
                           <caption>Table 5:	Adverse Reactions (â¥10%) in Patients who Received FRUZAQLA and with a Difference Between Arms of â¥5% Compared to Placebo in FRESCO (All Grades)</caption>
                           <col width="46%"/>
                           <col width="13%"/>
                           <col width="14%"/>
                           <col width="13%"/>
                           <col width="14%"/>
                           <thead>
                              <tr>
                                 <th align="left" valign="top" styleCode="Lrule Rrule Botrule" rowspan="2">Adverse Reaction</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule" colspan="2">Fruquintinib (N=278)</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule" colspan="2">Placebo (N=137)</th>
                              </tr>
                              <tr>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">All Grades (%)</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">Grade 3 or 4 (%)</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">All Grades (%)</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">Grade 3 or 4 (%)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Vascular</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Hypertension<footnote ID="t5f1">Represents a composite of multiple related terms.</footnote>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">61</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">23</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">17</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.2</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Hemorrhage<footnoteRef IDREF="t5f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">28</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.1</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">14</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Renal</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Proteinuria<footnoteRef IDREF="t5f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">55</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">4.7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">30</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Skin and Subcutaneous</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Palmar-plantar erythrodysesthesia (hand-foot skin reactions)</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">49</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">11</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.9</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Respiratory</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Dysphonia<footnoteRef IDREF="t5f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">38</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.5</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Throat Pain</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">10</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.5</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Gastrointestinal</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Stomatitis<footnoteRef IDREF="t5f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">33</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.9</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Abdominal Pain<footnoteRef IDREF="t5f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">29</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">4</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">17</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Diarrhea<footnoteRef IDREF="t5f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">25</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">3.6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">5</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">General</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Fatigue<footnoteRef IDREF="t5f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">25</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.5</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">13</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Metabolism</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Anorexia<footnoteRef IDREF="t5f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">21</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.4</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">9</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Musculoskeletal</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Musculoskeletal Pain<footnoteRef IDREF="t5f1"/>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">22</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.2</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Back Pain</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">15</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.8</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Arthralgia</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">13</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.4</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.2</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Endocrine Disorders</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Hypothyroidism</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">17</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.2</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other clinically important adverse reactions (all grades) that occurred in &lt;10% of patients treated with FRUZAQLA included urinary tract infection (9%), rash (9%), upper respiratory tract infection (4.7%), proctalgia (3.6%), pneumonia (2.9%), and gastrointestinal perforation or fistula (2.2%).</paragraph>
                        <paragraph>Table 6 provides laboratory abnormalities observed in FRESCO.</paragraph>
                        <table ID="table6" width="80%">
                           <caption>Table 6:	Select Laboratory Abnormalities Worsening from Baseline Occurring in â¥20% of Patients in FRESCO</caption>
                           <col width="30%"/>
                           <col width="18%"/>
                           <col width="17%"/>
                           <col width="18%"/>
                           <col width="17%"/>
                           <thead>
                              <tr>
                                 <th align="left" valign="middle" styleCode="Lrule Rrule Botrule" rowspan="2">Laboratory<footnote ID="t6f1">Graded according to NCI CTCAE version 4.03.</footnote>
                                    <br/>Abnormality</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule" colspan="2">FRUZAQLA (N=278)<footnote ID="t6f2">Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: FRUZAQLA (range: 257-277) and placebo (range: 126-134).</footnote>
                                 </th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule" colspan="2">Placebo (N=137)<footnoteRef IDREF="t6f2"/>
                                 </th>
                              </tr>
                              <tr>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">All Grades<br/>(%)</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">Grade 3 or 4<br/>(%)</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">All Grades<br/>(%)</th>
                                 <th align="center" valign="middle" styleCode="Rrule Botrule">Grade 3 or 4<br/>(%)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Chemistry</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Creatinine Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">87</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">75</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Glucose Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">43</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.1</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">31</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">3.0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Aspartate Aminotransferase Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">42</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">3.6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">31</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Alkaline Phosphatase Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">40</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">4.3</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">34</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">6</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Bilirubin Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">39</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">4.7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">34</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">8</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Alanine Aminotransferase Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">33</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.2</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">18</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Sodium Decreased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">33</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">31</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">5</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Urate Increased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">26</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">26</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">22</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">22</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Calcium Decreased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">25</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.4</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">13</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Potassium Decreased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">22</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">1.8</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">15</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">2.3</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Hematology</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Rrule Toprule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Platelets Decreased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">29</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">3.6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">6</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.7</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule Toprule">Â Â Â Hemoglobin Decreased</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">23</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">0.7</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">33</td>
                                 <td align="center" valign="middle" styleCode="Rrule Toprule">4.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other clinically relevant laboratory abnormalities (all grades) that occurred in &lt;20% of patients treated with FRUZAQLA included pancreatic enzymes increased (4.3%).</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="b447df00-8273-438c-97d7-740cb438999e"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7. DRUG INTERACTIONS</title>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Strong or Moderate CYP3A Inducers: Avoid concomitant use. (<linkHtml href="#S7.1">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="a6971485-8202-4a30-b31c-6da0daae7c1e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1.	Effects of Other Drugs on FRUZAQLA</title>
                     <text>
                        <paragraph>
                           <content styleCode="Underline">Strong CYP3A Inducers</content>
                        </paragraph>
                        <paragraph>Avoid concomitant use of drugs that are strong CYP3A inducers with FRUZAQLA.</paragraph>
                        <paragraph>Concomitant use with a strong CYP3A inducer may decrease fruquintinib C<sub>max</sub> and AUC <content styleCode="Italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may reduce the efficacy of FRUZAQLA.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Moderate CYP3A Inducers</content>
                        </paragraph>
                        <paragraph>If possible, avoid concomitant use of drugs that are moderate CYP3A inducers with FRUZAQLA. If it is not possible to avoid concomitant use of a moderate CYP3A inducer and fruquintinib, continue to administer FRUZAQLA at the recommended dosage.</paragraph>
                        <paragraph>Concomitant use with a moderate CYP3A inducer may decrease fruquintinib C<sub>max</sub> and AUC <content styleCode="Italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may reduce the efficacy of FRUZAQLA.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="96e6e2e5-d1c4-47bc-9e40-e90e1652c858"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8. USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Advise not to breastfeed. (<linkHtml href="#S8.2">8.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="05e5df91-9c14-48cb-8989-1b00c6d5cd7c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1. Pregnancy</title>
                     <effectiveTime value="20250206"/>
                     <component>
                        <section>
                           <id root="f89ffded-144e-4d23-be3e-14fbfafc70e0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on findings in animal studies and its mechanism of action, FRUZAQLA can cause fetal harm when administered to a pregnant woman. In an embryo-fetal developmental study in pregnant rats, oral administration of fruquintinib during the period of organogenesis resulted in teratogenicity and embryo lethality at exposures below the clinical exposure <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. There are no data on the use of FRUZAQLA in pregnant women. Advise pregnant women of the potential risk to a fetus.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="544536f3-6117-45cd-8b5b-6b69d1e2f55c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                           <component>
                              <section>
                                 <id root="9107d0a8-1595-4e36-a8b8-1d8b397bfc56"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In an embryo-fetal developmental study in pregnant rats, daily oral administration of fruquintinib at doses â¥0.1 mg/kg [approximately 0.2 times the recommended clinical dose of 5 mg based on body surface area (BSA)] during the period of organogenesis resulted in fetal external (edema and head and tail abnormalities), visceral, and skeletal malformations. At doses of 0.25 mg/kg (approximately 0.5 times the recommended clinical dose of 5 mg based on BSA), an increase in post-implantation loss and reduction in live fetuses was observed.</paragraph>
                                 </text>
                                 <effectiveTime value="20250206"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="dc442059-271d-40fc-a730-af4a8816f279"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2. Lactation</title>
                     <effectiveTime value="20250206"/>
                     <component>
                        <section>
                           <id root="8805bc69-58e4-4ad5-91fd-ca798df10b22"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data regarding the presence of fruquintinib or its metabolites in human milk or its effects on a breastfed child or on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with FRUZAQLA and for 2 weeks after the last dose.</paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="c58dd0d4-62fb-41d1-b0e3-8df2613af2aa"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3. Females and Males of Reproductive Potential</title>
                     <text/>
                     <effectiveTime value="20250206"/>
                     <component>
                        <section>
                           <id root="21bd23af-4c3a-4beb-8511-78b51ef3383c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify pregnancy status of females of reproductive potential prior to initiating FRUZAQLA.</paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="db3077a2-c200-4389-8593-57a2b320e3ee"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                           <component>
                              <section>
                                 <id root="caa57dd7-675e-40ac-ab5f-01ea3dce3b11"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females and Males</content>
                                    </paragraph>
                                    <paragraph>Females of childbearing potential and males with female partners of childbearing potential should use effective contraception during treatment and for 2 weeks after the last dose of FRUZAQLA <content styleCode="italics">[see <linkHtml href="#S5.11">Warnings and Precautions (5.11)</linkHtml> and <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                                    <paragraph>
                                       <content styleCode="underline">Infertility</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Females and Males</content>
                                    </paragraph>
                                    <paragraph>There are no data on the effects of fruquintinib on human fertility. Based on findings in animal studies, FRUZAQLA may impair female fertility <content styleCode="italics">[see <linkHtml href="#S13.1"> Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250206"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="18755acd-dbfa-4a4b-a6f5-e977837f8fea"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4. Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of FRUZAQLA in patients younger than 18 years of age have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="5c941446-a0f4-4784-aac5-24904f7f08f9"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5. Geriatric Use</title>
                     <text>
                        <paragraph>In FRESCO-2, 212 (46%) patients who received FRUZAQLA were â¥65 years of age and older, of whom 43 (20%) of patients were â¥75 years. There were no observed overall differences in safety and effectiveness of FRUZAQLA in geriatric compared to younger patients.</paragraph>
                        <paragraph>Of the total number of FRUZAQLA-treated patients in the FRESCO study, 50 (18%) were 65 years of age and older, and one patient was â¥75 years. There were no observed overall differences in safety and effectiveness of FRUZAQLA in geriatric compared to younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="e598d374-5de4-4c9f-963d-dc750c22ba58"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6.	Hepatic Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment is recommended for patients with mild hepatic impairment (total bilirubin less than or equal to the ULN with AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN with any AST <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>FRUZAQLA has not been sufficiently studied in patients with moderate hepatic impairment (total bilirubin greater than 1.5 times and less than 3 times ULN and any AST). FRUZAQLA is not recommended for use in patients with severe hepatic impairment (total bilirubin greater than 3 times ULN and any AST).</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="2af26183-721d-4e49-b5f6-1f0bd7678d32"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11. DESCRIPTION</title>
               <text>
                  <paragraph>Fruquintinib is a kinase inhibitor with the chemical name 6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-<content styleCode="italics">N</content>,2-dimethyl-1-benzofuran-3-carboxamide. Its molecular formula is C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>5</sub>, which corresponds to a molecular weight of 393.39 g/mol. Fruquintinib has the following chemical structure:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Fruquintinib is a white to off-white powder with a dissociation constant (pK<sub>a</sub>) of 2.78. The aqueous solubility of fruquintinib is pH-dependent with a solubility of 0.9 Î¼g/mL at pH 6.8 that increases under acidic conditions to 129.9 Î¼g/mL at pH 1.</paragraph>
                  <paragraph>FRUZAQLA (fruquintinib) capsules for oral administration contain 1 mg or 5 mg of fruquintinib. The inactive ingredients are corn starch, microcrystalline cellulose, and talc. The 1 mg capsule shell contains FD&amp;C Yellow No. 5 (tartrazine), FD&amp;C Yellow No. 6 (sunset yellow FCF), gelatin, and titanium dioxide. The 5 mg capsule shell contains FD&amp;C Blue No. 1 (brilliant blue FCF), FD&amp;C Red No. 40 (allura red AC), gelatin, and titanium dioxide. The printing ink for 1 mg and 5 mg capsules contains butanol, dehydrated alcohol, ferrosoferric oxide, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac and strong ammonia solution.</paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fruzaqla01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="1c59f8c8-aac2-47bd-b50c-08649377ee81"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12. CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250206"/>
               <component>
                  <section ID="S12.1">
                     <id root="ae8b2f5e-964a-4139-99a1-db86fadd9ea1"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1. Mechanism of Action</title>
                     <text>
                        <paragraph>Fruquintinib is a small molecule kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 with IC<sub>50</sub> values of 33, 35, and 0.5 nM, respectively. In vitro studies showed fruquintinib inhibited VEGF-mediated endothelial cell proliferation and tubular formation. In vitro and in vivo studies showed fruquintinib inhibited VEGF-induced VEGFR-2 phosphorylation. In vivo studies showed fruquintinib inhibited tumor growth in a tumor xenograft mouse model of colon cancer.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="d9f2d4e2-f5cf-4280-8b35-de06365959c1"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2. Pharmacodynamics</title>
                     <text>
                        <paragraph>Fruquintinib exposure-response relationships and the time course of pharmacodynamic response are unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                     <component>
                        <section>
                           <id root="64c30531-b02b-4a95-9f45-9d825da5bbba"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>A mean increase in QTc interval &gt;20 milliseconds (ms) was not observed at the approved recommended dosage.</paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="6a356571-32bf-4a8a-af83-d0de0262cf76"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3. Pharmacokinetics</title>
                     <text>
                        <paragraph>The fruquintinib steady-state geometric mean (% coefficient of variation [CV]) maximum concentration (C<sub>max</sub>) is 300 ng/mL (28%) and area under the concentration-time curve for the dosing interval (AUC<sub>0-24h</sub>) is 5880 ngâh/mL (29%) at the recommended dosage. The fruquintinib C<sub>max</sub> and AUC<sub>0-24h</sub> are dose-proportional across the dosage range of 1 to 6 mg (0.2 to 1.2 times the recommended dosage). Fruquintinib steady state is achieved after 14 days with a mean AUC<sub>0-24h</sub> accumulation of 4-fold.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                     <component>
                        <section>
                           <id root="60c519c6-3018-4065-adb8-be9498d46c66"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>The fruquintinib median (min, max) time to C<sub>max</sub> is approximately 2 hours (0, 26 hours).</paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                           <component>
                              <section>
                                 <id root="33553b88-e493-4bc2-863c-61c1acf4b6a7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Food</content>
                                    </paragraph>
                                    <paragraph>No clinically significant differences in fruquintinib pharmacokinetics were observed following administration of a high-fat meal (800 to 1000 calories, 50% fat).</paragraph>
                                 </text>
                                 <effectiveTime value="20250206"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="1f22dd53-607e-4ec9-b495-afbbe41e1a9b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The mean (SD) apparent volume of distribution of fruquintinib is approximately 46 (13) L. Plasma protein binding of fruquintinib is approximately 95%.</paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="6b0a9bfd-056d-461e-aa39-6de441bcc1bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The fruquintinib mean (SD) elimination half-life is approximately 42 (11) hours and the apparent clearance is 14.8 (4.4) mL/min.</paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                           <component>
                              <section>
                                 <id root="1a528271-686f-49a2-aac5-db7f820750d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Fruquintinib is primarily eliminated by CYP450 and non-CYP450 (i.e., sulfation and glucuronidation) metabolism. CYP3A and to a lesser extent CYP2C8, CYP2C9, and CYP2C19 are the CYP450 enzymes involved in fruquintinib metabolism.</paragraph>
                                 </text>
                                 <effectiveTime value="20250206"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="4e0f6263-b22f-4f18-b54e-2160ce310de8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Following oral administration of a 5 mg radiolabeled fruquintinib dose, approximately 60% of the dose was recovered in urine (0.5% unchanged) and 30% of the dose was recovered in feces (5% unchanged).</paragraph>
                                 </text>
                                 <effectiveTime value="20250206"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9e1f4dad-3a5e-4976-9d4a-1af707af6f4f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in the pharmacokinetics of fruquintinib were observed based on age (18 to 82 years), sex, race (Asian, Black, and White), ethnicity (Hispanic/Latino vs. non-Hispanic/Latino), body weight (48 to 108 kg), mild to severe renal impairment (CLcr 15 to 89 mL/min estimated by the Cockcroft-Gault equation), mild hepatic impairment (total bilirubin less than or equal to ULN with AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN with any AST).</paragraph>
                              <paragraph>The effect of moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN and any AST) on fruquintinib pharmacokinetics is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f5886dba-c09e-4299-b7f0-52d857343816"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                           <component>
                              <section>
                                 <id root="6e1614ad-6760-4a0c-a867-d03262c63b92"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Clinical Studies and Model-Informed Approaches</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250206"/>
                                 <component>
                                    <section>
                                       <id root="b8539d4d-d5b4-474a-a51b-f1fa4a5f68da"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="Underline">Strong CYP3A inducers:</content> Fruquintinib C<sub>max</sub> decreased by 12% and AUC<sub>inf</sub> by 65% following concomitant use with rifampin (strong CYP3A inducer).</paragraph>
                                       </text>
                                       <effectiveTime value="20250206"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="857c83ff-92ba-463a-a76d-dd22586d0c99"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="Underline">Moderate CYP3A inducers:</content> Fruquintinib C<sub>max</sub> is predicted to decrease by 4% and AUC<sub>inf</sub> by 32% following concomitant use with efavirenz (moderate CYP3A inducer).</paragraph>
                                       </text>
                                       <effectiveTime value="20250206"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="89869605-b6ef-4e25-b2dc-e654fa1d5116"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="Underline">Other Drugs:</content> No clinically significant differences in fruquintinib pharmacokinetics were observed when used concomitantly with itraconazole (strong CYP3A inhibitor) or rabeprazole (proton pump inhibitor; gastric acid reducing agent).</paragraph>
                                          <paragraph>No clinically significant differences in the pharmacokinetics of the following drugs were observed when used concomitantly with fruquintinib: dabigatran etexilate (P-gp substrate), or rosuvastatin (BCRP substrate).</paragraph>
                                       </text>
                                       <effectiveTime value="20250206"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="d00d67d7-d972-4515-bcf5-740619fe7487"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro Studies</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250206"/>
                                 <component>
                                    <section>
                                       <id root="63d6384f-bfa8-4db1-bb54-737843b0e216"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="Underline">Cytochrome P450 Enzymes:</content> Fruquintinib is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A, or an inducer of CYP1A2, CYP2B6, CYP3A.</paragraph>
                                       </text>
                                       <effectiveTime value="20250206"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="b13313ef-f6f2-4700-953e-99b9ca6fd245"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="Underline">Transporter Systems:</content> Fruquintinib is not a substrate of P-glycoprotein (P-gp), organic anion transporting polypeptide (OATP)1B1 or OATP1B3. Fruquintinib is not an inhibitor of OATP1B1, OATP1B3, organic anion transporter (OAT)1, OAT3, organic cation transporter (OCT)2, multidrug and toxin extrusion protein (MATE)1, or MATE2-K.</paragraph>
                                       </text>
                                       <effectiveTime value="20250206"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="64c3f6d3-77a7-4e91-93b0-f84f4ef1b013"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13. NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250206"/>
               <component>
                  <section ID="S13.1">
                     <id root="eaaa9384-5cc9-47dd-a80c-6bcce061cd58"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1. Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been conducted with fruquintinib.</paragraph>
                        <paragraph>Fruquintinib was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay or clastogenic in the in vitro Chinese hamster ovary chromosome aberration assay. Fruquintinib was not genotoxic in the in vivo rat micronucleus or alkaline comet assays.</paragraph>
                        <paragraph>In a fertility and early embryonic development study in rats, post-implantation loss was observed at doses approximately equal to the recommended clinical dose of 5 mg based on BSA. </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="03adee5d-49c6-40e1-b8d9-957d38e62944"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2. Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>In repeat dose toxicity studies in rats, daily oral administration of fruquintinib at doses â¥0.6 mg/kg (approximately 1.2 times the recommended clinical dose of 5 mg based on BSA) resulted in broken or lost teeth.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="83b1d100-c89f-4815-bcb4-07b82155cbe6"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14. CLINICAL STUDIES</title>
               <text/>
               <effectiveTime value="20250206"/>
               <component>
                  <section ID="S14.1">
                     <id root="33d46546-1893-4246-abdb-df48b02df200"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1. Metastatic Colorectal Cancer</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">FRESCO-2 Study</content>
                        </paragraph>
                        <paragraph>The efficacy of FRUZAQLA was evaluated in FRESCO-2 (NCT04322539), an international, multicenter, randomized, double-blind, placebo-controlled study that enrolled 691 patients with metastatic colorectal cancer who had disease progression during or after prior treatment with fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapy, an anti-VEGF biological therapy, if RAS wild type, an anti-EGFR biological therapy, and trifluridine/tipiracil, regorafenib, or both. Patients with an ECOG PS â¥2, left ventricular fraction â¤50%, systolic blood pressure &gt;140 mm Hg or diastolic blood pressure &gt;90 mm Hg, urine protein â¥1 g/24h, or untreated brain metastases were ineligible. Randomization was stratified by prior use of trifluridine/tipiracil or regorafenib (trifluridine/tipiracil vs. regorafenib vs. trifluridine/tipiracil and regorafenib), RAS status (wild type vs. mutant), and duration of metastatic disease (â¤18 months vs. &gt;18 months).</paragraph>
                        <paragraph>Patients were randomized (2:1) to receive FRUZAQLA 5 mg orally once daily (N=461) for the first 21 days of each 28-day cycle plus BSC or placebo (N=230) plus BSC. Patients received either FRUZAQLA or placebo until disease progression or unacceptable toxicity. The major efficacy outcome measure was overall survival (OS) and an additional efficacy outcome measure was progression-free survival (PFS) as determined by investigators according to RECIST v1.1.</paragraph>
                        <paragraph>The study population characteristics were median age of 64 years (range: 25 to 86), with 47% â¥65 years of age; 56% male; 81% White, 9% Asian, 2.9% Black or African American, and 0.7% Native Hawaiian/Pacific Islander; 43% had an ECOG PS of 0 and 57% had an ECOG PS of 1, and 63% had <content styleCode="italics">RAS</content>-mutant tumors. Eighteen percent of the patients were enrolled in North America, 72% in Europe, and 10% in Asia Pacific (Japan and Australia) region.</paragraph>
                        <paragraph>All patients received prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy; 96% received prior anti-VEGF therapy, 39% received prior anti-EGFR therapy, 91% received trifluridine/tipiracil, 48% received regorafenib, and 39% received both trifluridine/tipiracil and regorafenib.</paragraph>
                        <paragraph>The addition of FRUZAQLA to BSC resulted in a statistically significant improvement in OS and PFS compared to placebo plus BSC (see <linkHtml href="#table7">Table 7</linkHtml>, <linkHtml href="#fig1">Figure 1</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="underline">FRESCO Study</content>
                        </paragraph>
                        <paragraph>The efficacy of FRUZAQLA was evaluated in FRESCO (NCT02314819), a multicenter, randomized, double-blind, placebo-controlled study conducted in China that enrolled 416 patients with metastatic colorectal cancer who had disease progression during or after prior treatment with fluoropyrimidine-, oxaliplatin, or irinotecan-based chemotherapy. Patients older than 75 years of age, Eastern Cooperative Oncology Group (ECOG) performance status (PS) â¥2, left ventricular ejection fraction â¤50%, systolic blood pressure &gt;140 mm Hg or diastolic blood pressure &gt;90 mm Hg, urine protein â¥1 g/24h, or brain metastases were ineligible. Randomization was stratified by prior use of VEGF inhibitors (yes vs. no) and <content styleCode="italics">K-RAS</content> status (wild type vs. mutant).</paragraph>
                        <paragraph>Patients were randomized (2:1) to receive FRUZAQLA 5 mg orally once daily (N=278) for the first 21 days of each 28-day cycle plus BSC or placebo (N=138) plus BSC. Patients received either FRUZAQLA or placebo until disease progression or unacceptable toxicity. The major efficacy outcome measure was OS and an additional efficacy outcome measure was PFS as determined by investigators according to RECIST v1.1.</paragraph>
                        <paragraph>The study population characteristics were median age of 56 years (range: 23 to 75), with 19% â¥65 years of age; 61% male; 100% Asian; 27% had an ECOG PS of 0 and 73% had an ECOG PS of 1 (73%), and 44% had <content styleCode="italics">K-RAS</content> mutant tumors.</paragraph>
                        <paragraph>All patients received prior treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy; 30% of patients received prior anti-VEGF therapy, and 14% received prior anti-EGFR therapy.</paragraph>
                        <paragraph>The addition of FRUZAQLA to BSC resulted in a statistically significant improvement in OS compared to placebo plus BSC (see <linkHtml href="#table7">Table 7</linkHtml>, <linkHtml href="#fig2">Figure 2</linkHtml>).</paragraph>
                        <table ID="table7" width="80%">
                           <caption>Table 7:	Efficacy Results from FRESCO-2 and FRESCO Studies</caption>
                           <col width="20%" align="left" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Lrule Rrule" colspan="2">FRESCO-2</th>
                                 <th styleCode="Lrule Rrule" colspan="2">FRESCO</th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule" valign="top">Endpoint</th>
                                 <th styleCode="Rrule">FRUZAQLA<br/> + BSC<br/> N=461</th>
                                 <th styleCode="Lrule Rrule">Placebo<br/> + BSC<br/> N=230</th>
                                 <th styleCode="Rrule">FRUZAQLA<br/> + BSC<br/> N=278</th>
                                 <th styleCode="Rrule">Placebo<br/> + BSC<br/> N=138</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5">Abbreviations: CI=confidence interval; N=number of patients; OS=overall survival; PFS=progression-free survival</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="5" align="left">
                                    <content styleCode="bold">OS</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Number of patients with event (%)</td>
                                 <td styleCode="Rrule">317 (69%)</td>
                                 <td styleCode="Lrule Rrule">173 (75%)</td>
                                 <td styleCode="Rrule">188 (68%)</td>
                                 <td styleCode="Rrule">109 (79%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Median in months (95% CI)</td>
                                 <td styleCode="Rrule">7.4<br/> (6.7, 8.2)</td>
                                 <td styleCode="Lrule Rrule">4.8<br/> (4.0, 5.8)</td>
                                 <td styleCode="Rrule">9.3<br/> (8.2, 10.5)</td>
                                 <td styleCode="Rrule">6.6<br/> (5.9, 8.1)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Hazard Ratio<footnote ID="t7f1">The Hazard Ratio and its 95% CI were estimated using a stratified Cox proportional hazards model.</footnote>
                                    <br/>(95% CI)</td>
                                 <td styleCode="Rrule" colspan="2">0.66 (0.55, 0.80)</td>
                                 <td styleCode="Lrule Rrule" colspan="2">0.65 (0.51, 0.83)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">P</content>-Value<footnote ID="t7f2">
                                       <content styleCode="italics">P</content>-Value (2-sided) was calculated using a stratified log-rank test.</footnote>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">&lt;0.001</td>
                                 <td styleCode="Lrule Rrule" colspan="2">&lt;0.001</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="5" align="left">
                                    <content styleCode="bold">PFS</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Number of patients with event (%)</td>
                                 <td styleCode="Rrule">392 (85%)</td>
                                 <td styleCode="Lrule Rrule">213 (93%)</td>
                                 <td styleCode="Rrule">235 (85%)</td>
                                 <td styleCode="Rrule">125 (91%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Median in months (95% CI)</td>
                                 <td styleCode="Rrule">3.7<br/> (3.5, 3.8)</td>
                                 <td styleCode="Lrule Rrule">1.8<br/> (1.8, 1.9)</td>
                                 <td styleCode="Rrule">3.7<br/> (3.7,4.6)</td>
                                 <td styleCode="Rrule">1.8<br/> (1.8, 1.8)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Hazard Ratio<footnoteRef IDREF="t7f1"/>
                                    <br/>(95% CI)</td>
                                 <td styleCode="Rrule" colspan="2">0.32 (0.27, 0.39)</td>
                                 <td styleCode="Lrule Rrule" colspan="2">0.26 (0.21, 0.34)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">P</content>-Value<footnoteRef IDREF="t7f2"/>
                                    <footnote ID="t7f3">
                                       <content styleCode="italics">P</content>-Value for the PFS analysis in FRESCO was not included due to lack of multiplicity adjustment for this analysis.</footnote>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">&lt;0.001</td>
                                 <td styleCode="Lrule Rrule" colspan="2">-</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="fig1" width="100%" styleCode="Noautorules">
                           <caption>Figure 1: Kaplan-Meier Curve for Overall Survival in FRESCO-2</caption>
                           <col width="100%" align="center" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM2"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="fig2" width="100%" styleCode="Noautorules">
                           <caption>Figure 2: Kaplan-Meier Curve for Overall Survival in FRESCO</caption>
                           <col width="100%" align="center" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM3"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250206"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>figure1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="fruzaqla02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM3">
                           <text>figure2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="fruzaqla03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="50a0b9c7-bd30-46ef-8f4a-067cb4c17568"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16. HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>How Supplied</paragraph>
                  <table width="80%">
                     <col width="20%" align="center" valign="top"/>
                     <col width="30%" align="center" valign="top"/>
                     <col width="30%" align="center" valign="middle"/>
                     <col width="20%" align="center" valign="top"/>
                     <thead>
                        <tr styleCode="Botrule">
                           <th styleCode="Lrule Rrule">Capsule Strength</th>
                           <th styleCode="Lrule Rrule">Description</th>
                           <th styleCode="Lrule Rrule">Package Configuration</th>
                           <th styleCode="Lrule Rrule">NDC Number</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">1 mg</td>
                           <td styleCode="Rrule">Size 3 hard gelatin capsule with yellow opaque cap and white opaque body, imprinted with âHM013â over â1 mgâ on the body in black ink</td>
                           <td styleCode="Lrule Rrule" rowspan="2">White high-density polyethylene (HDPE) bottle with child-resistant closure packaged in a carton.<br/> Each bottle contains 21 capsules.</td>
                           <td styleCode="Rrule">63020-210-21</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">5 mg</td>
                           <td styleCode="Rrule">Size 1 hard gelatin capsule with a red opaque cap and white opaque body, imprinted with âHM013â over â5 mgâ on the body in black ink</td>
                           <td styleCode="Rrule">63020-225-21</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <section>
                     <id root="e8fcd71f-7f02-4a19-98ff-fb276505b8ad"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and handling</content>
                        </paragraph>
                        <paragraph>Store at 20Â°C to 25Â°C (68Â°F to 77Â°F). Brief exposure to 15Â°C and 30Â°C (59Â°F to 86Â°F) permitted (see USP Controlled Room Temperature).</paragraph>
                        <paragraph>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="c3697918-c0b6-4e3b-b166-8c02953b9264"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17. PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#S_PI">Patient Information</linkHtml>).</paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <section>
                     <id root="c3348eaf-1309-42cb-a04d-26e8ef2bbe0c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypertension</content>
                        </paragraph>
                        <paragraph>Advise patients to undergo regular blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if symptoms from hypertension occur including severe headache, lightheadedness, or new neurologic symptoms <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7600d946-6620-4364-b9ba-e0d44f209721"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hemorrhages</content>
                        </paragraph>
                        <paragraph>Advise patients that FRUZAQLA may increase the risk of bleeding and to contact their healthcare provider for unusual, severe, or persistent bleeding, bruising, or symptoms of bleeding, such as lightheadedness <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="cb34199e-9ac3-4fea-b1e0-ba00d20372a6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infections</content>
                        </paragraph>
                        <paragraph>Advise patients to contact their healthcare provider if they experience signs and symptoms of infection <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="001287bc-49d5-4efd-935e-4c3a944d8cf8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Gastrointestinal Perforation</content>
                        </paragraph>
                        <paragraph>Advise patients to contact a healthcare provider immediately if they experience severe abdominal pains, or other symptoms of gastrointestinal perforation or fistula <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8a7824a4-c938-45a8-8b40-51f9e5ad02d9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hepatotoxicity</content>
                        </paragraph>
                        <paragraph>Advise patients that they will need to undergo laboratory tests to monitor liver function and to report any new symptoms indicating hepatic toxicity or failure <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="64ca6e15-4f9c-4ae7-b097-a1c016244488"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Proteinuria</content>
                        </paragraph>
                        <paragraph>Advise patients that they will need to undergo laboratory tests to monitor for proteinuria and to contact their healthcare provider for signs or symptoms of proteinuria <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0393fcaa-1de4-493c-87ca-36201cbe284d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Palmar-plantar erythrodysesthesia (PPE)</content>
                        </paragraph>
                        <paragraph>Advise patients to contact their healthcare provider for progressive or intolerable rash  <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="9a16d584-8ee9-4a4d-b6b3-021eb2154a60"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Posterior Reversible Encephalopathy Syndrome (PRES)</content>
                        </paragraph>
                        <paragraph>Advise patients to immediately contact their healthcare provider for new onset or worsening neurological function <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0042d462-8ff1-4635-bc44-ed0b7b1caa39"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Impaired Wound Healing</content>
                        </paragraph>
                        <paragraph>Advise patients that FRUZAQLA may impair wound healing. Advise patients to inform their healthcare provider of any planned surgical procedure <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c54eefae-09c2-4f5b-9555-e0bd637c00a9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Arterial Thrombosis</content>
                        </paragraph>
                        <paragraph>Advise patients to seek immediate medical attention for new onset chest pain or acute neurologic symptoms consistent with myocardial infarction or stroke <content styleCode="italics">[see <linkHtml href="#S5.10">Warnings and Precautions (5.10)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b0e79e27-189b-4ddf-8132-49ff26e5b10f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Allergic Reactions to FD&amp;C Yellow No. 5 (Tartrazine) and No. 6 (Sunset Yellow FCF)</content>
                        </paragraph>
                        <paragraph>Advise patients that FRUZAQLA 1 mg contains FD&amp;C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons or in patients who also have aspirin hypersensitivity <content styleCode="italics">[see <linkHtml href="#S5.11">Warnings and Precautions (5.11)</linkHtml>]</content>.</paragraph>
                        <paragraph>Advise patients FRUZAQLA 1 mg contains FD&amp;C Yellow No. 6 (sunset yellow FCF) which may cause allergic-type reactions <content styleCode="italics">[see <linkHtml href="#S5.11">Warnings and Precautions (5.11)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="006a0bec-633e-47e9-957c-e383984ad3e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <paragraph>Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform females of the risk to a fetus and potential loss of pregnancy <content styleCode="italics">[see <linkHtml href="#S5.12">Warnings and Precautions (5.12)</linkHtml> and <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of FRUZAQLA <content styleCode="italics">[see <linkHtml href="#S5.12">Warnings and Precautions (5.12)</linkHtml> and <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks following the last dose of FRUZAQLA <content styleCode="italics">[see <linkHtml href="#S5.11">Warnings and Precautions (5.11)</linkHtml> and <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="01bd8309-0700-4aa2-9632-37bd506321cd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise patients not to breastfeed during treatment with FRUZAQLA and for 2 weeks after the last dose of FRUZAQLA <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential that FRUZAQLA may cause post-implantation loss <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>, <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="e4694043-fe92-46e6-8e97-c1692bba57a9"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Takeda Pharmaceuticals America, Inc.</content>
                     <br/>Cambridge, MA 02142</paragraph>
                  <paragraph>FRUZAQLA and  <renderMultiMedia referencedObject="MM6"/> are trademarks of HUTCHMED Group Enterprises Limited, used under license.</paragraph>
                  <paragraph>TAKEDA and <renderMultiMedia referencedObject="MM7"/> are registered trademarks of Takeda Pharmaceutical Company Limited.</paragraph>
                  <paragraph>Â©2025 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.</paragraph>
                  <paragraph>FRU380 R2</paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>logo1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fruzaqla06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>logo2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fruzaqla07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S_PI">
               <id root="f324a944-1ace-4404-a2df-5e151f9a98d0"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%" align="left" valign="top"/>
                     <col width="45%" align="left" valign="top"/>
                     <col width="52%" align="left" valign="top"/>
                     <tfoot>
                        <tr>
                           <td colspan="2" align="left">This Patient Information has been approved by the U.S. Food and Drug Administration.</td>
                           <td colspan="1" align="right">Revised: 2/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3" align="center">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>FRUZAQLA<sup>Â®</sup> (fru-zahk-la)<br/>(fruquintinib)<br/>capsules</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">What is FRUZAQLA?</content>
                              </paragraph>
                              FRUZAQLA is a prescription medicine used to treat adults with colon or rectal cancer that has spread to other parts of the body (metastatic colorectal cancer [mCRC]) and who have received previous treatment with certain anti-cancer medicines.<br/>
                              It is not known if FRUZAQLA is safe and effective in children.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">Before taking FRUZAQLA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have high blood pressure.</item>
                                 <item>have bleeding problems.</item>
                                 <item>have an infection.</item>
                                 <item>have liver or kidney problems.</item>
                                 <item>plan to have surgery or have had recent surgery. You should stop taking FRUZAQLA at least 2 weeks before your planned surgery. Your healthcare provider will tell you when you can start FRUZAQLA again after your surgery. See <content styleCode="bold">
                                       <linkHtml href="#whatare">âWhat are the possible side effects of FRUZAQLA?â</linkHtml>
                                    </content>
                                 </item>
                                 <item>have recently had a blood clot, stroke, or heart attack.</item>
                                 <item>are allergic to FD&amp;C Yellow No. 5 (tartrazine) or FD&amp;C Yellow No. 6 (sunset yellow FCF). See <content styleCode="bold">
                                       <linkHtml href="#whatare">âWhat are the possible side effects of FRUZAQLA?â</linkHtml>
                                    </content>
                                 </item>
                                 <item>are pregnant or plan to become pregnant. FRUZAQLA can harm your unborn baby. You should not become pregnant during treatment with FRUZAQLA.<br/>
                                    <content styleCode="bold">Females who can become pregnant:</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>Your healthcare provider will do a pregnancy test before you start treatment with FRUZAQLA.</item>
                                       <item>Use effective birth control (contraception) during treatment and for 2 weeks after your last dose of FRUZAQLA.</item>
                                       <item>Tell your healthcare provider right away if you become pregnant during treatment with FRUZAQLA.</item>
                                    </list>
                                    <content styleCode="bold">Males with female partners who can become pregnant:</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>Use effective birth control during treatment and for 2 weeks after your last dose of FRUZAQLA.</item>
                                       <item>Tell your healthcare provider right away if your partner becomes pregnant during your treatment with FRUZAQLA.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if FRUZAQLA passes into your breast milk. Do not breastfeed during treatment and for 2 weeks after your last dose of FRUZAQLA.</item>
                              </list>
                              Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. FRUZAQLA may affect the way other medicines work, and other medicines may affect how FRUZAQLA works.<br/>Especially tell your healthcare provider if you take blood thinners (anticoagulants).<br/>Know the medicines you take. Keep a list of your medicines to show to your healthcare provider and pharmacist when you get a new medicine.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">How should I take FRUZAQLA?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Take FRUZAQLA exactly as your healthcare provider tells you.</item>
                                 <item>Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with FRUZAQLA if you have certain side effects. <content styleCode="bold">Do not</content> change your dose or stop taking FRUZAQLA unless your healthcare provider tells you.</item>
                                 <item>You will usually take FRUZAQLA 1 time a day for 21 days (3 weeks) and then stop for 7 days (1 week). This is 1 cycle of treatment. Repeat this cycle for as long as your healthcare provider tells you.</item>
                                 <item>Take FRUZAQLA about the same time each day with or without food and swallow the capsule whole.</item>
                                 <item>If you miss a dose of FRUZAQLA, you can take the missed dose within 12 hours on the same day. If more than 12 hours have passed, take your regularly scheduled dose the next day at the usual time. <content styleCode="bold">Do not</content> take 2 doses at the same time to make up for the missed dose.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> take another dose if you vomit after taking FRUZAQLA. Take your regularly scheduled dose the next day at the usual time.</item>
                                 <item>If you take too much FRUZAQLA, call your healthcare provider or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <paragraph ID="whatare">
                                 <content styleCode="bold">What are the possible side effects of FRUZAQLA?<br/>FRUZAQLA may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">High blood pressure (hypertension).</content> High blood pressure is common with FRUZAQLA and can also be severe. Your healthcare provider will check your blood pressure before starting treatment with FRUZAQLA, 1 time every week for the first month of treatment, and then at least 1 time a month or more often if needed during treatment. Your healthcare provider may prescribe medicine to treat your high blood pressure if needed. Tell your healthcare provider if you get any of the following symptoms of hypertension during treatment:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>severe headache</item>
                                 <item>lightheadedness or dizziness</item>
                                 <item>confusion</item>
                                 <item>changes in vision</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>chest pain</item>
                                 <item>trouble breathing</item>
                                 <item>nosebleeds</item>
                                 <item>vomiting</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Severe bleeding (hemorrhage).</content> FRUZAQLA can cause bleeding that can be serious and may lead to death. Tell your healthcare provider if you get any of the following symptoms of bleeding during treatment:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>unusual, severe, or bleeding that will not stop</item>
                                 <item>bruising</item>
                                 <item>lightheadedness</item>
                                 <item>vomiting blood or your vomit looks like coffee grinds</item>
                                 <item>blood in the stool or black stool that looks like tar</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>blood in the urine or urine that looks red, pink or brown</item>
                                 <item>coughing up blood or blood clots</item>
                                 <item>menstrual bleeding that is heavier than normal</item>
                                 <item>unusual vaginal bleeding</item>
                                 <item>nose bleeds that happen often</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Infections.</content> FRUZAQLA can increase the risk of infections, including serious infections that can lead to death. The most common infections with FRUZAQLA happened in the urinary tract, nose or throat, and lungs. Tell your healthcare provider if you get any of the following symptoms of infection during treatment:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>fever </item>
                                 <item>severe cough with or without an increase in mucus (sputum) production </item>
                                 <item>severe sore throat</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>trouble breathing</item>
                                 <item>burning or pain when you urinate</item>
                                 <item>redness, swelling or pain in any part of the body</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">A tear in your stomach or intestinal wall (gastrointestinal perforation).</content> FRUZAQLA can cause gastrointestinal perforation that can be serious and may lead to death. Tell your healthcare provider right away, if you get any of the following symptoms of gastrointestinal perforation during treatment:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>severe stomach (abdominal) pain or stomach pain that does not go away</item>
                                 <item>vomiting or vomiting blood</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>blood in the stool or black stool that looks like tar</item>
                                 <item>fever or chills</item>
                                 <item>nausea</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Liver problems</content>. Increased liver enzymes in your blood are common with FRUZAQLA and can also be severe and may lead to death. Your healthcare provider will do blood tests before and during treatment with FRUZAQLA to check for liver problems. Tell your healthcare provider if you get any of the following symptoms of liver problems during treatment:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>yellowing of your skin or the white part of your eyes</item>
                                 <item>dark colored (tea colored) urine</item>
                                 <item>pain in your right upper stomach-area (abdomen)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>loss of appetite</item>
                                 <item>nausea or vomiting</item>
                                 <item>bleeding or bruising</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Protein in your urine (proteinuria)</content>. Protein in your urine is common with FRUZAQLA and can also be severe. Your healthcare provider will check your urine for protein before starting and during treatment with FRUZAQLA. Tell your healthcare provider if you have to urinate more than usual, or if you get swelling of your face, hands, arms, legs, or feet during treatment.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Hand-foot skin reactions (Palmar-Plantar Erythrodysesthesia [PPE])</content>. Hand-foot skin reactions are common with FRUZAQLA and can also be severe. Tell your healthcare provider if you get a severe rash or redness, pain, blisters, bleeding, or swelling on the palms of your hands or soles of your feet during treatment.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Posterior Reversible Encephalopathy Syndrome (PRES).</content> PRES is a serious condition that can happen in your brain during treatment with FRUZAQLA. Tell your healthcare provider right away if you get any of the following symptoms during treatment:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>headache</item>
                                 <item>seizures</item>
                                 <item>confusion</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>changes in vision </item>
                                 <item>problems thinking</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Wound healing problems.</content> Wounds may not heal properly during treatment with FRUZAQLA. Tell your healthcare provider if you plan to have any surgery before starting FRUZAQLA or during treatment.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>You should stop taking FRUZAQLA at least 2 weeks before planned surgery.</item>
                                 <item>Your healthcare provider will tell you when you may start taking FRUZAQLA again after surgery.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Blood clots in your blood vessels (arteries).</content> FRUZAQLA can cause blood clots or blockage in your blood vessels that may lead to heart attack, stroke, or death. Get medical help right away if you get any of the following symptoms during treatment:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>severe chest pain or pressure</item>
                                 <item>pain in your arms, legs, back, neck or jaw</item>
                                 <item>shortness of breath</item>
                                 <item>numbness or weakness of your face, arm, or leg, especially on one side of your body</item>
                                 <item>feeling lightheaded or faint</item>
                                 <item>sweating more than usual</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>sudden confusion, trouble talking, or understanding things</item>
                                 <item>trouble walking</item>
                                 <item>sudden severe headache</item>
                                 <item>sudden vision changes in one or both eyes</item>
                                 <item>dizziness, or loss of balance or coordination</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Allergic reactions to FD&amp;C Yellow No. 5 and FD&amp;C Yellow No. 6</content>. FRUZAQLA 1 mg capsules contain the inactive ingredients FD&amp;C Yellow No. 5 (tartrazine) and FD&amp;C Yellow No. 6 (sunset yellow FCF). FD&amp;C Yellow No. 5 (tartrazine) can cause allergic-type reactions (including bronchial asthma) in certain people, especially people who also have an allergy to aspirin. FD&amp;C Yellow No. 6 (sunset yellow FCF) can also cause allergic reactions. Tell your healthcare provider if you get hives, rash, or trouble breathing during treatment with FRUZAQLA.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">The most common side effects of FRUZAQLA include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>voice changes or hoarseness</item>
                                 <item>stomach-area (abdominal) pain</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>diarrhea</item>
                                 <item>weakness, lack of strength and energy, and feeling very tired or sleepy (asthenia) </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">FRUZAQLA may cause fertility problems in females, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.<br/>
                              <br/>These are not all of the possible side effects of FRUZAQLA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">How should I store FRUZAQLA?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store FRUZAQLA at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</item>
                                 <item>Keep FRUZAQLA dry and away from moisture.</item>
                                 <item>The FRUZAQLA bottle comes with a child resistant closure.</item>
                                 <item>Safely throw away (discard of) any unused FRUZAQLA.</item>
                              </list>
                              <content styleCode="bold">Keep FRUZAQLA and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">General information about the safe and effective use of FRUZAQLA.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use FRUZAQLA for a condition for which it was not prescribed. Do not give FRUZAQLA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about FRUZAQLA that is written for health professionals.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">What are the ingredients in FRUZAQLA?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> fruquintinib<br/>
                              <content styleCode="bold">Inactive ingredients:</content> corn starch, microcrystalline cellulose, talc<br/>
                              Capsule shell:<br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>1 mg capsule: FD&amp;C Yellow No. 5 (tartrazine), FD&amp;C Yellow No. 6 (sunset yellow FCF), gelatin, and titanium dioxide</item>
                                 <item>5 mg capsule: FD&amp;C Blue No. 1 (brilliant blue FCF), FD&amp;C Red No. 40 (allura red AC), gelatin, and titanium dioxide</item>
                              </list>
                              Printing ink: butanol, dehydrated alcohol, ferrosoferric oxide, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, and strong ammonia solution.<br/>
                              <br/>
                              <paragraph>Distributed by:<br/> Takeda Pharmaceuticals America, Inc.<br/>Cambridge, MA 02142<br/>FRUZAQLA and  <renderMultiMedia referencedObject="MM6"/> are trademarks  of HUTCHMED Group Enterprises Limited, used under license.<br/>TAKEDA and <renderMultiMedia referencedObject="MM7"/> are registered trademarks of Takeda Pharmaceutical Company Limited.<br/>Â©2025 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.<br/>For more information, go to <linkHtml href="www.fruzaqla.com">www.fruzaqla.com</linkHtml> or call 1-844-217-6468.<br/>FRU380 R2</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250206"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e6ef4843-1e88-40ad-849a-fab841d4bef2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 mg Capsules</title>
               <text>
                  <paragraph>NDC 63020-210-21</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Fruzaqla<sup>â¢</sup>
                     </content>
                     <br/>(fruquintinib) capsules</paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg</content>
                  </paragraph>
                  <paragraph>Contains FD&amp;C Yellow No. 5<br/>(tartrazine) and No. 6 (sunset yellow<br/>FCF) as color additives.</paragraph>
                  <paragraph>21 capsules</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Takeda</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 1 mg Capsules</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fruzaqla04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c8016dc9-a8d6-483c-a08d-5deeb6bd6694"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 mg Capsules Label</title>
               <text>
                  <paragraph>NDC 63020-210-21</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Fruzaqla<sup>â¢</sup>
                     </content>
                     <br/>(fruquintinib) capsules</paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg</content>
                  </paragraph>
                  <paragraph>21 capsules</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Takeda</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>PRINCIPAL DISPLAY PANEL - 1 mg Capsules</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fruzaqla08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="ffff8772-0353-42d5-b87a-1a103e341346"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mg Capsules</title>
               <text>
                  <paragraph>NDC 63020-225-21</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Fruzaqla<sup>â¢</sup>
                     </content>
                     <br/>(fruquintinib) capsules</paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mg</content>
                  </paragraph>
                  <paragraph>21 capsules</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Takeda</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>PRINCIPAL DISPLAY PANEL - 1 mg Capsules</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fruzaqla05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="531f569e-5b9f-464a-a539-5ce932b811fd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mg Capsules Label</title>
               <text>
                  <paragraph>NDC 63020-225-21</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Fruzaqla<sup>â¢</sup>
                     </content>
                     <br/>(fruquintinib) capsules</paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mg</content>
                  </paragraph>
                  <paragraph>21 capsules</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Takeda</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM9"/>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>PRINCIPAL DISPLAY PANEL - 1 mg Capsules</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fruzaqla09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>